Vaneltix Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding, Private
- Established
- 1997-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://vaneltix.com
Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Vaneltix Pharma, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06394830
- Locations
- 🇺🇸
Arizona Urology Specialists, Tucson, Arizona, United States
🇺🇸Valley Urology, Inc., Fresno, California, United States
🇺🇸Prestige Medical Group, Tustin, California, United States
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
Phase 2
Recruiting
- Conditions
- Bladder Pain SyndromeInterstitial Cystitis
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Vaneltix Pharma, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05737121
- Locations
- 🇺🇸
IC Study LLC, Escondido, California, United States
🇺🇸University of California Los Angeles Center for Women's Pelvic Health, Los Angeles, California, United States
🇺🇸The Continence Center Medical Group, Inc dba Southern California Continence Center, Newport Beach, California, United States
© Copyright 2025. All Rights Reserved by MedPath